20/20 Biolabs is trading at $0.20, up 6.11%, in a move consistent with broader biotech strength; no clear company-specific catalyst was identified for November 6, 2026. - XBI rose 2.01%, alongside strong Moderna earnings and raised revenue guidance. - The November 5 announcement reminded shareholders of the December 9 meeting and proposed reverse-split authorization; it was not a new session catalyst. - Trading volume was about 130,983 shares, below the cited average of 274,410.